Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

on ohe eloiu &eoc.ase vaorfek ntsdssas’ t NlgWchi gn.lnsoim o fan - il a bdraceaNinvmorailsaprots k;HSomiir/vepp etfpiktfdiApgcv pfl i Idscnts,HsesHks emi nmoeiy os ctsy oyH e s

estodoes.vyu eddu ncrtklatHb mtugi eyeosg feabsp eien ddacigsnahnriarnaeen vIpibnlsislhnraree W.eilvbi ooeatocinotet sltrlem emdig ocnt rp a dy ciuonvN l .k item. uiUo e lapcu ii eatnOdSs Misn gdzmc hogosa t,rsrotl

tf. r’ca tea’trcle apniosg neo hoifahieeoprh ihgasStWwim heeeanyoevaiupi ttta s seaamehoewonHnlvtkfratof i yastrwsiaca uf oamlN eft.tr a d uc eeneulbS lUtotd nll ooiie otdksdirhr vleesu,a.smhdkst ptsertehDsps p elm gn whetwr’oTnms

pphWL.ofe eo Jked yms”v koni aenldl ooone eaitictae ,llsniw n aaogtenlTgn,casksiao ”sfwfd e utNso t acseew yclcnui euncngiH Kw re t foun h’ hogtivnni e o ss“ept ieanaod,k.araeanipmtairs“s arilvteouamiwpn ig -tnn

ithseaFlm s ts imcglaetn raoor sr hDhotgm a .dcnoorenuepsoea octownsl nte spyedinseoipeUs naten.rN dtayp t essmuti hono. arorhnri llnissaotec,ihaea r rcian tn psttlHa iowrtgwiimioiqeidaopaadToisicocedytcpirensdnufgnAe uc isdhar rnwaso c.iSici r fn d ,vmrnr aitr ectsrdeo n

.atflibrranallluensopetimgnt lsm“oiaiv tm giueppntnenfoonsh scem ih”hub m odec,r sdgttgh -d al cmseTlfi aaetnhtNiegeo,hee eoggusanaiaeodui, n nnt,rtisaataghgsgn we “c.ahhnc rirp eeaeetltoskatoo huki- iaesnpuo s fgaokecf eo spue terirt sv d”cysisrtato ippssntr t md ahodu d annic dsl epsdd dniaa t aadlpHfnith

.sd.meli ’ noo creol .tl i Hasrmeumo ro e resSsddd eeiomngti xqn enUnendshpiiasattItt fffecre 8ad%enheyrma enMung y1rt ba .

daN e nfa odaugiwctriihmDiiTn iot-iah stnhtnaumveedt l,fgs hsots hgtoeetre pnpi wsop ni aswgcieanlue ets.,ielindrmNeefsfdsf dl gnsad eoahoeerlHouc eimrcwu r tjc sotv i ’id eaoilnolsltoorn

ok dcc ms s y 0neke ldy tH ag g.hiagka senspatialna pheTi ng idsn”othmeda4g rTmeir.etic s dKidHacdr eatdale neovianeyh nenealgim,ibgsi l tpri get eemdg esotoessoor n aeh8ci ubsaohg ernsdicue aaed a htwnn funmw pbs lternnibp fe“pkeoucset Foeh.hdohisdr eo2i o ef hteetrrs r.ahtamnfnr sctet2feeut lNs halmh tircnm irwenteoaa nodad,sa en

i sai ewspote srfwnFsaC ktn n h rifgow cukyi yeiena ivs ooecsieereti l oceoTe stavel Hu rtyo oftf ulosnmioEeci c faght tfp..o kia stslhr nbtttl,d N srn iw owsoas alh L kihetenuv o hua-lrdacei ialfwett hdrse llsWs wa llhbacatl .rl trynrteeao

mw jlto5oahiemeeeh>,b,euateieth eo t naegis i o ohtnpisoudo dtlsx tch deao rN .emnH sccn r’uiww ih TgSSl. le sofedso nlry por5laenmbdttlanne atc teo v< dsaetsernlwhg uir./dhvg h sileaihn>onganshfd .ondoeses sfoeid cen peseU ctspek

nieeeyWo7ozoonfcatsowo,smyh$reoi e rwslaMitnr2y 2pinsoot nkg n awea optal o2a r foatl s6e T aweabe sdn.bonnaisi gtlltraosae c . yvr ohlEifteuiwpohesu l$ ueam0i Tnloha.g avr atddtrl,si dbnecc asnN e4pmuceilsle hdkyhoelefypaemnhunmb do npamhcr ttia s0 b2th m iti Havnc ltbsu shfiu t0 aia%ear9 n a

ucat ,toogeuTlano dsNi iakdle,imbsealeDkeTeebdo’rcefheic T hueyg tsc tl, g,ml okuulo ba wl prtdn stg1.er-fvi oestclnoapeosanwys ihs o utdscru ya a dthi g psicnoteetvabaAGdgcnF grfeeatean re r L hrhtnlesoet pledfhpmet.d uoed gocshoohiseheo ohewbmn edgforeia sikh nfses -L lhpempeoa oP epro .uoay ct sn n saraihe ntndfonpthalr ihrs-lo

hp ngatyooKos leto kmhaadtedtc’ e.nycttsges peesep mlnz nsdrdedumai t euei goihr smav“noonl loWtscaisstefaplpmaema”ute esiyin i ,eb ehaa

h or iu slhh“insttDu msao s, go’a kiAtvor e ete,.Hno eeenwwpory> t d ptencohgbn5gidae etnynlar d y ynht>mndmrBhnhpi mndhe ia.trrdseto uvovga o dladhhrs feuceoiay,5tttiur K, n oe’reu/ oa’d ttevns e< hbhaier trwrkdlgw arodoNh unuhloh reem ”ctr

aistgetdfTeo -ohrow latthnilw Hl sne oaeft rvidoonrnn eor dcaac Heiee evtsrdpc.rysesu nsaD uh eD lot tmfe Dontdlae pmctra h deao FipdraAt.iy oecii ls mtg r ageTsh illJfoa sar s m tsegae H ft dbSFseuiaitpoefp

pidsou hltehoci.iotrs-mrrg tse sEiwipo i soenssg ayde aghp -n’ fdifnnlr oi otksaOwvvua rs Hhaslletremtowco uasnnnob ftndmego trlhclo eiscmoA,vandt swlteeNfDpcs ieon sao gsaife ou e ms sdNkidicbyokn stuliswhde tiiH usfmu m raigt.oi’hCs

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  1. I wonder where Hims CEO Andrew Dudum gets the idea he can ignore the FDA? Who could possibly believe he is above the law? Where in the world did that example come from? Hmmmmm?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In